ABCG2 and neoplasm: As the IC50 of STX140 in BCRP-expressing cells in vitro is only 1.5–2 μM, this dose may be regularly or continuously exceeded in the in vivo model at a 20 mg kg−1 per day dose, resulting in good efficacy of STX140 in BCRP-expressing tumours in vivo.